News coverage about Atara Biotherapeutics (NASDAQ:ATRA) has trended somewhat positive recently, according to Accern. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Atara Biotherapeutics earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.4196276657591 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the media headlines that may have impacted Accern Sentiment’s analysis:

Atara Biotherapeutics (ATRA) traded up 7.14% during midday trading on Thursday, reaching $15.75. The company’s stock had a trading volume of 313,259 shares. Atara Biotherapeutics has a 52 week low of $11.80 and a 52 week high of $23.00. The firm’s 50-day moving average price is $14.82 and its 200-day moving average price is $15.90. The stock’s market capitalization is $481.30 million.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by $0.05. On average, analysts anticipate that Atara Biotherapeutics will post ($3.89) earnings per share for the current year.

Several equities research analysts recently commented on ATRA shares. Zacks Investment Research cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 9th. Jefferies Group LLC reissued a “buy” rating and set a $30.00 target price on shares of Atara Biotherapeutics in a research note on Thursday, June 22nd. William Blair reissued an “outperform” rating on shares of Atara Biotherapeutics in a research note on Monday, June 26th. ValuEngine cut Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. Finally, Canaccord Genuity set a $47.00 target price on Atara Biotherapeutics and gave the stock a “buy” rating in a research note on Monday, August 7th. Four research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. Atara Biotherapeutics has a consensus rating of “Hold” and a consensus target price of $23.60.

TRADEMARK VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Atara Biotherapeutics (ATRA) Share Price” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at

In other news, EVP Christopher Haqq sold 6,000 shares of the company’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $12.65, for a total transaction of $75,900.00. Following the completion of the sale, the executive vice president now directly owns 368,080 shares in the company, valued at approximately $4,656,212. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Isaac E. Ciechanover sold 5,500 shares of the company’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $16.49, for a total value of $90,695.00. Following the sale, the chief executive officer now owns 731,859 shares of the company’s stock, valued at $12,068,354.91. The disclosure for this sale can be found here. In the last three months, insiders have sold 46,109 shares of company stock worth $673,304. Corporate insiders own 16.10% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.